Spyre Therapeutics, LLC

Spyre Therapeutics initiates Phase 1 trials for two anti-TL1A molecules, SPY002, with potential for quarterly or twice-yearly dosing, aiming to improve efficacy and convenience over first-generation treatments. Interim safety, PK, and PD data expected in Q2 2025, with plans for Phase 2 studies in ulcerative colitis and other inflammatory diseases in 2025. The company has a strong financial position with over $630M in cash, cash equivalents, and marketable securities.

Spyre Therapeutics to participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 7:30 a.m. Eastern time. Webcast available at ir.spyre.com.

You need to enable JavaScript to run this app.

SPY001, an extended half-life monoclonal antibody targeting α4β7, showed favorable safety and PK/PD profiles, supporting potential Q6M maintenance dosing and optimized Phase 2 induction regimens in IBD treatment. Spyre plans to initiate a Phase 2 platform trial in mid-2025, including SPY001, SPY002 (TL1A), SPY003 (IL-23), and combinations.

Spyre Therapeutics to report interim Phase 1 SPY001 trial results on Nov 12, 2024, hosting a conference call and webcast at 8:00am ET.

Spyre Therapeutics granted 90,000 shares of common stock to two non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan. The stock options, approved on November 1, 2024, have a 10-year term and an exercise price of $33.98 per share, vesting quarterly over four years.

Spyre Therapeutics to present at Guggenheim's Inaugural Healthcare Innovation Conference on Nov 13, Stifel 2024 Healthcare Conference on Nov 18, and Jefferies London Healthcare Conference on Nov 20.

Spyre Therapeutics announced updated pipeline progress and timelines, including first-in-human dosing of SPY003 (anti-IL-23) expected Q1 2025. Preclinical data presented at UEGW showed SPY003's robust activity, with a half-life extended three-fold compared to risankizumab. Combination therapies with SPY003 and other antibodies demonstrated enhanced efficacy in IBD models.